, Columnist
Brent Saunders's New Model Will Be Tested in 2017
Curbing prices and buying early stage drugs is a risky path for the fast-moving CEO.
This article is for subscribers only.
Brent Saunders's rise has been swift. He's risen so far, so fast, and in such an unusual way that the whole pharma industry is watching to see whether he'll fail -- or should be imitated.
About seven years ago, Saunders led the consumer health division at Schering-Plough. Now he's in the captain's chair at Allergan plc, the $66 billion pharma giant he helped build from what was once a smallish New Jersey generics company called Watson Pharmaceuticals.